Pentagestrone acetate

Chemical compound
Pentagestrone acetate
Clinical data
Trade namesGestovis, Gestovister
Other namesPGA; Gestovis; 17α-Acetoxyprogesterone 3-cyclopentyl enol ether
Routes of
administration
By mouth
Drug classProgestogen; Progestin; Progestogen ether; Progestogen ester
Identifiers
  • [(8R,9S,10R,13S,14S,17R)-17-acetyl-3-cyclopentyloxy-10,13-dimethyl-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate
CAS Number
  • 1178-60-5
PubChem CID
  • 10321047
ChemSpider
  • 8496511
UNII
  • 3Y30374T6H
Chemical and physical data
FormulaC28H40O4
Molar mass440.624 g·mol−1
3D model (JSmol)
  • Interactive image
  • CC(=O)C1(CCC2C1(CCC3C2CC=C4C3(CCC(=C4)OC5CCCC5)C)C)OC(=O)C
InChI
  • InChI=1S/C28H40O4/c1-18(29)28(32-19(2)30)16-13-25-23-10-9-20-17-22(31-21-7-5-6-8-21)11-14-26(20,3)24(23)12-15-27(25,28)4/h9,17,21,23-25H,5-8,10-16H2,1-4H3/t23-,24+,25+,26+,27+,28+/m1/s1
  • Key:NSRLWNNZHGRGJS-JVACCQEYSA-N

Pentagestrone acetate (PGA), sold under the brand names Gestovis and Gestovister, is a progestin which was described in the literature in 1960 and was introduced by Vister in Italy in 1961.[1][2][3] It is the 3-cyclopentyl enol ether of 17α-hydroxyprogesterone acetate.[4] PGA, along with quingestrone (the 3-cyclopentyl enol ether of progesterone), is said to have very similar properties to those of dydrogesterone, a pure progestogen and close analogue of progesterone.[5]

PGA is orally active, was provided in 10 and 20 mg capsules, and has been used to treat habitual abortion and menstrual disorders at a dosage of 10 to 20 mg/day.[6] It has been said to have equivalent potency to intramuscular progesterone.[6] The combination of 20 mg/day PGA and 100 μg/day mestranol is an effective ovulation inhibitor in women.[7][8] The effective dosage of PGA in the menstrual delay test has been studied.[9]

Chemistry

PGA, also known as 17α-acetoxyprogesterone 3-cyclopentyl enol ether, is a synthetic pregnane steroid and a derivative of progesterone and 17α-hydroxyprogesterone.[1]

See also

References

  1. ^ a b Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 943–. ISBN 978-1-4757-2085-3.
  2. ^ Drugs Available Abroad. Gale Research. 1991. ISBN 978-0-8103-7177-4.
  3. ^ List PH, Hörhammer L (12 March 2013). "Pentagestrone". Chemikalien und Drogen Teil A: N-Q. Springer-Verlag. pp. 508–. ISBN 978-3-642-65035-2.
  4. ^ Wermuth DG (2 May 2011). "Designing Prodrugs and Bioprecursors". In Wermuth CG (ed.). The Practice of Medicinal Chemistry. Academic Press. pp. 731–. ISBN 978-0-08-056877-5.
  5. ^ Revue générale des sciences pures et appliquées et bulletin de l'Association française pour l'avancement des sciences. Société d'édition d'enseignement supérieur. 1964. [[...] Ercoli (1960) developed cyclopentyl enol ethers of progesterone (Luteovis) and acetoxy progesterone (Gestovis), which have almost exactly the same properties as dydrogesterone.]
  6. ^ a b "Gestovis". South African Medical Journal. 40 (5): 99. January 1966. ISSN 0256-9574. Comopharm (Pty) Limited. on behalf of Vister Laboratories, announce the introduction of Gestovis, and supply the following information: Gestovis is a new highly effective oral progesterone derivative (cyclopentyl enol-ether of 17-alpha-acetoxy progesterone) for the treatment of threatened and habitual abortion and menstrual disturbances. Gestovis is efficacious orally at the same dose as parenterally administered progesterone. Dosage. 10 - 20 mg. daily or as necessary. Presentation. Available in capsules of 10 and 20 mg.
  7. ^ Pincus G (3 September 2013). "The Inhibition of Ovulation". The Control of Fertility. Elsevier. pp. 221–. ISBN 978-1-4832-7088-3.
  8. ^ Current Medicine and Drugs. 1962. p. 32. Gestovis (3-cyclo-pentyl-enol ether of 17a acetoxyprogesterone) is a potent non-oestrogenic preparation but does not give very good cycle control. In doses of 20 mg daily from the fifth to the twenty-fifth day of the cycle it will inhibit ovulation.
  9. ^ Edgren RA, Sturtevant FM (August 1976). "Potencies of oral contraceptives". American Journal of Obstetrics and Gynecology. 125 (8): 1029–1038. doi:10.1016/0002-9378(76)90804-8. PMID 952300.
  • v
  • t
  • e
Progestogens and antiprogestogens
Progestogens
(and progestins)
PRTooltip Progesterone receptor agonists
Antiprogestogens
SPRMsTooltip Selective progesterone receptor modulators
PRTooltip Progesterone receptor antagonists
See also
Progesterone receptor modulators
Androgens and antiandrogens
Estrogens and antiestrogens
List of progestogens
  • v
  • t
  • e
PRTooltip Progesterone receptor
Agonists
Mixed
(SPRMsTooltip Selective progesterone receptor modulators)
Antagonists
mPRTooltip Membrane progesterone receptor
(PAQRTooltip Progestin and adipoQ receptor)
Agonists
Antagonists
See also
Receptor/signaling modulators
Progestogens and antiprogestogens
Androgen receptor modulators
Estrogen receptor modulators
List of progestogens
Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e
Stub icon

This article about a steroid is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e